08:00 , Dec 20, 2010 |  BC Week In Review  |  Company News

Cancer Targeted Technology, Bayer deal

The companies will collaborate to optimize a PET imaging agent based on Cancer Targeted Technology's enzyme inhibitor scaffold which targets the prostate-specific membrane antigen ( PSMA ; FOLH1 ; GCPII ) biomarker. Cancer Targeted Technology...